Why the study?
As disease-modifying therapies for ATTR-CM become accessible, clinical indicators of disease progression are needed to guide clinical decision-making and personalize treatment strategies.
Population
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Design
Review
Key result
Markers such as outpatient diuretic intensification increased mortality risk by HR 1.79, NT-proBNP progression by HR 1.81, and myocardial ECV increase by HR 2.02 at 12 months in ATTR-CM patients, supporting their use as indicators of disease progression.
Authors
Loading...
These markers may support ATTR-CM monitoring; leaves open prospective validation before guiding practice.
Monitoring disease progression in ATTR-CM requires a multiparametric approach incorporating clinical, biomarker, and imaging parameters to guide clinical decision-making and trial design.
Porcari et al. (2026) conducted a review in Patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including wild-type and variant forms, varying stages including early diagnosis and advanced involvement. Markers such as outpatient diuretic intensification increased mortality risk by HR 1.79, NT-proBNP progression by HR 1.81, and myocardial ECV increase by HR 2.02 at 12 months in ATTR-CM patients, supporting their use as indicators of disease progression.